Bristol-Myers (BMY) discontinues late-stage colorectal cancer study
bristol myers squib BMY experienced a setback when it decided to cancel the late-stage trial RELATIVITY-123. In this Phase III, randomized, open-label, multicenter study, approximately 700 adult patients with stable microsatellites received a fixed-dose combination of Opdivo (nivolumab) and leratorimab, combined with Stivarga (regorafenib) or It was evaluated in comparison with trifluridine + tipiracil (TAS-102). […]